Skip to main content
OpenTrials

Clinical trial condition

Recurrence

Explore clinical trials studying Recurrence. Study availability and eligibility vary by location and protocol.

2,359 public trials 538 recruiting studies
Refine in advanced search Browse all conditions

Recurrence trial results

Recruiting

A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)

NCT05519085

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Disease Attributes, +17 more
Locations
  • Local Institution - 0366 Los Alamitos, California, United States
  • Local Institution - 0272 San Diego, California, United States
  • Local Institution - 0273 West Hollywood, California, United States
  • Local Institution - 0381 Aurora, Colorado, United States
View all 266 locations
View Trial Details
Recruiting

A Study to Assess Adverse Events and How Intravenous (IV) Pivekimab Sunirine Moves Through the Body in Pediatric Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML)

NCT07306832

Conditions
Acute Myeloid Leukemia, Disease Attributes, Hematologic Diseases, +9 more
Locations
  • Lucile Packard Children's Hospital /ID# 276015 Palo Alto, California, United States
  • New York Medical College /ID# 275597 Valhalla, New York, United States
  • Tristar Centennial Medical Center /ID# 275831 Nashville, Tennessee, United States
  • Perth Children'S Hospital /ID# 275673 Perth, Western Australia, Australia
View all 13 locations
View Trial Details
Recruiting

A Study of Ruxolitinib and Duvelisib in People With Lymphoma

NCT05010005

Conditions
Disease Attributes, Hematologic Diseases, Hemic and Lymphatic Diseases, +22 more
Locations
  • University of Miami (Data Collection Only) Miami, Florida, United States
  • Dana Farber Cancer Institute Boston, Massachusetts, United States
  • Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities) Basking Ridge, New Jersey, United States
  • Memorial Sloan Kettering Monmouth (Limited Protocol Activities) Middletown, New Jersey, United States
View Trial Details
Recruiting

Study to Evaluate Combined Treatment of Daratumumab, Bortezomib and Dexamethasone in PBL Patients.

NCT04915248

Conditions
Disease Attributes, Hemic and Lymphatic Diseases, Immune System Diseases, +13 more
Locations
  • A.O. Spedali Civili di Brescia - Ematologia Brescia, Italy
  • Istituto Scientifico San Raffaele, Unità Linfomi - Dipartimento Oncoematologia Milan, Italy
  • U.O. Ematologia AO di Padova Padova, Italy
  • Ematologia IRCCS Policlinico S. Matteo di Pavia Pavia, Italy
View all 18 locations
View Trial Details
Recruiting

Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator's Choice in Participants With Endometrial Cancer

NCT07166094

Conditions
Disease Attributes, Endometrial Cancer, Endometrial Neoplasms, +15 more
Locations
  • HonorHealth Research Inst Phoenix, Arizona, United States
  • Kaiser Permanente SoCal Irvine, California, United States
  • MedStar Washington Hospital Washington D.C., District of Columbia, United States
  • SMH - Sarasota - Main Campus Sarasota, Florida, United States
View all 171 locations
View Trial Details
Recruiting

A Phase 2 Study of PTX 100 in Patients With Relapsed/Refractory CTCL

NCT06854653

Conditions
CTCL, Disease Attributes, Hemic and Lymphatic Diseases, +15 more
Locations
  • City of Hope Comprehensive Cancer Cente Duarte, California, United States
  • University of California Irvine Irvine, California, United States
  • Yale Cancer Center New Haven, Connecticut, United States
  • Dana-Farber Cancer Institute Boston, Massachusetts, United States
View all 15 locations
View Trial Details
Recruiting

A Study of ARV-393 in Relapsed/Refractory Non-Hodgkin Lymphoma.

NCT06393738

Conditions
Disease Attributes, Hemic and Lymphatic Diseases, Immune System Diseases, +15 more
Locations
  • Clinical Trial Site New Haven, Connecticut, United States
  • Clinical Trial Site Detroit, Michigan, United States
  • Clinical Trial Site New Brunswick, New Jersey, United States
  • Clinical Trial Site New York, United States
View all 21 locations
View Trial Details
Recruiting

Study Evaluating the Efficacy of KITE-753 Versus Axicabtagene Ciloleucel in Participants With Relapsed or Refractory Large B-Cell Lymphoma After First-Line Therapy

NCT07479797

Conditions
Disease Attributes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, +2 more
Locations
  • City of Hope (City of Hope National Medical Center, City of Hope Medical Center) Duarte, California, United States
  • Stanford University Stanford, California, United States
  • Colorado Blood Cancer Institute Denver, Colorado, United States
  • Southeastern Regional Medical Center, Inc. dba City of Hope Atlanta Newnan, Georgia, United States
View all 19 locations
View Trial Details

Related conditions